Here is why Novo Nordisk A/S (NVO) is among the Best Longevity and Anti-Aging Stocks to Buy

With a short percentage of shares outstanding of 0.51%, Novo Nordisk A/S (NYSE:NVO) is among the 7 Best Longevity and Anti-Aging Stocks to Buy.

On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares.

Earlier, on June 11, Novo Nordisk A/S (NYSE:NVO) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency approved the Wegovy pill as an adjunct to a reduced-calorie diet and increased physical activity. The approval makes the therapy the first oral GLP-1 receptor agonist authorized for weight management in adults living with obesity or overweight who also have at least one weight-related medical condition. The decision was supported by data from the Phase 3 OASIS 4 clinical trial and expands Novo Nordisk’s obesity treatment portfolio by offering patients a non-injectable alternative to existing therapies.

Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in chronic conditions like diabetes and obesity. It is primarily known for developing lifesaving GLP-1 therapies like Ozempic and Wegovy, but it also targets the underlying metabolic and cardiovascular diseases that reduce lifespan.

READ NEXT: 10 Most Overvalued Quantum Computing Stocks According to Short Sellers and 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.

Disclosure: None.  Follow Insider Monkey on Google News.